Titlebook: Novel Antischizophrenia Treatments; Mark A. Geyer,Gerhard Gross Book 2012 Springer-Verlag Berlin Heidelberg 2012 Cognition.Neurotransmitte

結(jié)束

–DOX

Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia,riable neuropathology of schizophrenia strongly suggests that it is not currently, and may never be, correctable with drugs. In contrast, several forms of cognitive therapy have been demonstrated to have modest but lasting positive effects on cognition, symptoms, and functional outcomes in schizophr

隱士

Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment, they relate to behavioral, psychopharmacological, and cellular phenotypes of putative import for antipsychotic drug development. Mutant models appear to be heuristic at two main levels; firstly, by indicating the functional roles of neuronal components thought to be of relevance to the putative pat

BURSA

5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia,iple signal transduction pathways leading to engagement of a number of intracellular signaling molecules. Moreover, there are multiple allelic variants of the 5-HT. receptor and the receptor is subject to RNA editing in the coding regions. The complexity of this receptor is further emphasized by the

猛擊

Mri485

chemoprevention

Hangar

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications,mpliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of sympto

定點(diǎn)

patriarch